Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer

Inclusion Criteria:

- Cytologically or histologic confirmed non-small cell lung cancer, stage IIIB or IV or
recurrent after primary surgery or radiotherapy.

- ECOG PS 0-1

- 70 years of age or older

- Must have measurable disease

- ANC > 1500, platelets > 100,000

- Total bilirubin
- Able and willing to swallow and absorb oral medication

- Able and willing to sign consent

- Request archival diagnostic tissue for EGFR expression but not required

Exclusion Criteria:

- Proteinuria as demonstrated by UPC ratio >/= 1.0

- Prior treatment with an investigational or marketed inhibitor of the EGFR pathway or
anti-angiogenesis agent (includes thalidomide)

- Prior treatment for advanced stage disease, with the exception of surgery or
radiation (no systemic)

- History of gross hemoptysis within 1 month of enrollment unless treated with surgery
or radiation

- Evidence of bleeding diathesis or coagulopathy or other serious/acute internal
bleeding within 6 months of enrollment.

- Current, ongoing treatment with full dose warfarin or equivalent

- Current(within 10 days)use of aspirin (> 325mg/day) or other NSAID with antiplatelet
activity

- History of hemorrhagic or thrombotic stoke, TIA, or other CNS bleeding w/in last 6
months. Clinically significant PVD

- Known CNS disease except for treated brain mets.

- Squamous cell histology

- Blood pressure > 150/100 that cannot be ameliorated with standard anti-hypertensives

- History of hypertensive crisis or hypertensive encephalopathy

- NYHA grade II or > CHF

- History of MI within 6 months of enrollment

- Major surgery, open biopsy, significant trauma within 28 days of enrollment

- Pregnancy, lactation

- Abdominal or other fistula, abcess, perforation